Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease
Фолат, витамин B12 и общий сывороточный гомоцистеин при верифицированной болезни Альцгеймера
1998-11-01
SCID: 54.1/k84q9ezu
Discuss with AI
Alzheimer diseaseapolipoprotein E ε4folatetotal homocysteinevitamin B12
Figures from the paper
Abstract (AI)
BACKGROUND: Recent studies suggest that vascular disease may contribute to the cause of Alzheimer disease (AD). Since elevated plasma total homocysteine (tHcy) level is a risk factor for vascular disease, it may also be relevant to AD. OBJECTIVE: To examine the association of AD with blood levels of tHcy, and its biological determinants folate and vitamin B12. DESIGN: Case-control study of 164 patients, aged 55 years or older, with a clinical diagnosis of dementia of Alzheimer type (DAT), including 76 patients with histologically confirmed AD and 108 control subjects. SETTING: Referral population to a hospital clinic between July 1988 and April 1996. MAIN OUTCOME MEASURES: Serum tHcy, folate, and vitamin B12 levels in patients and controls at entry; the odds ratio of DAT or confirmed AD with elevated tHcy or low vitamin levels; and the rate of disease progression in relation to tHcy levels at entry. RESULTS: Serum tHcy levels were significantly higher and serum folate and vitamin B12 levels were lower in patients with DAT and patients with histologically confirmed AD than in controls. The odds ratio of confirmed AD associated with a tHcy level in the top third (> or = 14 micromol/L) compared with the bottom third (< or = 11 micromol/L) of the control distribution was 4.5 (95% confidence interval, 2.2-9.2), after adjustment for age, sex, social class, cigarette smoking, and apolipoprotein E epsilon4. The corresponding odds ratio for the lower third compared with the upper third of serum folate distribution was 3.3 (95% confidence interval, 1.8-6.3) and of vitamin B12 distribution was 4.3 (95% confidence interval, 2.1-8.8). The mean tHcy levels were unaltered by duration of symptoms before enrollment and were stable for several years afterward. In a 3-year follow-up of patients with DAT, radiological evidence of disease progression was greater among those with higher tHcy levels at entry. CONCLUSIONS: Low blood levels of folate and vitamin B12, and elevated tHcy levels were associated with AD. The stability of tHcy levels over time and lack of relationship with duration of symptoms argue against these findings being a consequence of disease and warrant further studies to assess the clinical relevance of these associations for AD.
Key Findings
1
Confirmed AD was associated with an adjusted odds ratio of 4.5 for tHcy in the top third (≥14 µmol/L) versus bottom third (≤11 µmol/L) of the control distribution (95% CI, 2.2–9.2).
2
Lower third of serum folate and vitamin B12 distributions were associated with increased odds of confirmed AD: folate OR 3.3 (95% CI, 1.8–6.3) and vitamin B12 OR 4.3 (95% CI, 2.1–8.8).
3
Patients with DAT and confirmed AD had significantly lower serum folate and vitamin B12 levels than controls.
4
Patients with clinically diagnosed dementia of Alzheimer type (DAT) and histologically confirmed AD had significantly higher serum total homocysteine (tHcy) levels than controls.
5
tHcy levels were stable over time and unrelated to symptom duration, and higher baseline tHcy predicted greater radiological disease progression over 3 years.
Research Object
Blood levels of serum total homocysteine, folate, and vitamin B12 in patients with Alzheimer disease and controls
Research Subject
Association between serum tHcy, folate, and vitamin B12 levels and Alzheimer disease (including odds of confirmed AD and relationship to disease progression)
Publication Details
Publication Date
1998-11-01
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest